NICE OK For BMS's Opdivo To Shake Up UK RCC Market, Bad News For Pfizer
Executive Summary
Bristol-Myers Squibb's Opdivo looks set to blow rivals out the water in renal cell carcinoma as NICE U-turns on negative recommendation, just weeks after the company revealed the full extent of the drug’s disappointment in first-line lung cancer.
You may also be interested in...
NICE Move On Cabometyx Gives BMS Longer To Make Opdivo Case In Second Line RCC
A NICE knock-back for Ipsen's Cabometyx in renal cell carcinoma (RCC) means less pressure on BMS's embattled Opdivo, but not for long if Ipsen is willing to compromise on price, warn analysts.
NICE Rejects BMS' Opdivo As Adult Kidney Cancer Treatment
The UK HTA NICE in draft guidance has rejected Bristol-Myers Squibb Co.'s Opdivo (nivolumab) as a therapy for previously treated advanced renal cell carcinoma in adults, saying the PD-1 inhibitor doesn't offer value for money. It added that it should also not be made available to such patients through the government-funded Cancer Drugs Fund, for the same reasons.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.